The India product patent is valid through 2029, while the Korean one is good for up to 2033, the company that focuses on neurological diseases said.
“The granted claims of the patents include the class of selective Alpha4 Beta2 and 5-HT 4 compounds respectively and are being developed as therapeutic agents for major depressive disorders and for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention Deficient Hyperactivity Disorder (ADHD), Huntington’s Disease, Narcolepsy, Parkinson and Schizophrenia,” it said.
The patents strengthen Suven’s “pipeline of molecules” in the area of central nervous system disorders, said CEO Venkat Jasti.
These cognitive disorders have high unmet medical need with huge market potential globally, Jasti added.
Suven Life Sciences is biopharmaceutical company and focuses on discovering, developing and commercializing new drugs aimed at nervous disorders.
Suven has 4 clinical stage compounds. The most advanced is SUVN-502, which is currently in Phase 2 clinical trial. It also has SUVN-G3031, which is ready for Phase 2 trial and SUVN-D4010, which has completed Phase 1.
The latest, SUVN-911, has started Phase 1 clinical trial.
It also has nine drug candidates currently in various stages of pre-clinical development. These are targeted at ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and pain.